#United States #Class Action #New Orleans #ClaimsFiler #Ultragenyx

Ultragenyx Shareholder Alert

Ultragenyx Pharmaceutical Inc. faces significant legal scrutiny as recent developments in a class action lawsuit have drawn attention from investors. ClaimsFiler, a service dedicated to providing shareholder information, has reminded affected investors that they need to file their lead plaintiff applications by April 6, 2026. This notice is particularly critical for those who acquired shares of Ultragenyx between August 3, 2023, and December 26, 2025.

Overview of the Lawsuit

The ongoing class action lawsuit against Ultragenyx was prompted by claims that the company's executives failed to disclose crucial information that could impact shareholders. On December 26, 2025, the company announced disappointing results from the Phase 3 Orbit and Cosmic studies associated with their drug, setrusumab (UX143), which is aimed at treating Osteogenesis Imperfecta. The company revealed that the trials did not produce statistically significant results in reducing fracture rates for patients, leading to substantial operational implications. Following this news, Ultragenyx’s stock plummeted approximately 42%, dramatically impacting investor value. Shares that were priced at $34.19 before the announcement fell to $19.72 by December 29, 2025.

Legal Implications

The lawsuit, registered under Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., in the United States District Court for the Southern District of New York, centers on allegations of federal securities law violations due to a failure to disclose material information during the critical class period.

Ultragenyx investors who believe they have incurred losses exceeding $100,000 due to the drop in share price following the company’s announcements are strongly encouraged to consult with legal professionals regarding their potential claims.

For further assistance, investors can contact ClaimsFiler or visit their website at ClaimsFiler or reach out at (844) 367-9658. Legal experts from Kahn Swick & Foti, LLC are available to evaluate individual circumstances and discuss potential next steps in the legal process.

Recovering Losses

ClaimsFiler aims to be a vital resource for retail investors seeking to recover profits from securities class action settlements. By registering for free, investors can gain access to vital information about ongoing class action lawsuits and the steps necessary to submit claims. Additionally, by submitting their portfolio transactional data, investors are notified about relevant securities cases that may affect their financial interests.

Investors are reminded of the urgency of the situation and the approaching deadline to ensure they do not miss the opportunity to file their claims. Protecting one’s investment through participation in class actions can be an essential step toward recovery.

For more information on filing claims and understanding the legal landscape surrounding class action lawsuits, ULtragenyx's shareholders should visit ClaimsFiler's website.

In conclusion, the unfolding legal developments surrounding Ultragenyx Pharmaceutical Inc. reaffirm the importance of transparency and accountability within corporations, particularly in the pharmaceutical industry where patient welfare and investor interests are profoundly intertwined.